Edition:
United States

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

2.75USD
2 Dec 2016
Change (% chg)

$-0.10 (-3.51%)
Prev Close
$2.85
Open
$2.90
Day's High
$2.90
Day's Low
$2.75
Volume
21,845
Avg. Vol
60,537
52-wk High
$5.09
52-wk Low
$2.41

ACRX.OQ

Chart for ACRX.OQ

About

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product... (more)

Overall

Beta: 3.06
Market Cap(Mil.): $140.53
Shares Outstanding(Mil.): 45.33
Dividend: --
Yield (%): --

Financials

  ACRX.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.98 -- --
ROI: -41.11 -1.09 14.95
ROE: -203.62 -2.39 16.29

BRIEF-Acelrx Pharma says amended loan and security deal with Hercules Tech II and Hercules Capital Inc

* Among other things, amendment extends interest-only period from October 1, 2016 to April 1, 2017 - SEC filing

Oct 03 2016

BRIEF-AcelRx Pharmaceuticals initiates late-stage study of its painkiller

* Initiates phase 3 study of Zalviso in patients with moderate-to-severe acute post-operative pain Source text for Eikon: Further company coverage:

Sep 27 2016

AcelRx's opioid painkiller succeeds in key study

AcelRx Pharmaceuticals Inc said its experimental opioid painkiller was well tolerated in post-operative patients, including those with organ impairment and the elderly, in a late-stage study.

Sep 15 2016

UPDATE-1-AcelRx's opioid painkiller succeeds in key study

Sept 15 AcelRx Pharmaceuticals Inc said its experimental opioid painkiller was well tolerated in post-operative patients, including those with organ impairment and the elderly, in a late-stage study.

Sep 15 2016

BRIEF-Acelrx reports positive results for ARX-04 in Phase 3 registration trial

* Reports positive results for ARX-04 (sufentanil sublingual tablet, 30 mcg), including in elderly patients and patients with organ impairment, in third Phase 3 registration trial, SAP303

Sep 15 2016

BRIEF-Acelrx Pharmaceuticals posts results from phase 3 study of ARX-04

* Acelrx pharmaceuticals presents results from phase 3 study of ARX-04 in the emergency department at the international society for burn injuries

Aug 29 2016

BRIEF-AcelRx Pharmaceuticals says ARX-04 phase 3 trial met primary endpoint

* Overall ARX-04 was well tolerated in study, with 79% of patients reporting no adverse events

Aug 15 2016

BRIEF-Acelrx Pharmaceuticals Q2 loss per share $0.24

* Acelrx Pharmaceuticals provides corporate update and reports second quarter and six months 2016 financial results

Jul 28 2016

BRIEF-Acelrx enters controlled equity offering sales agreement

* Entered controlled equity offering sales agreement to offer and sell shares of common stock par value $0.001 per share of up to $40 million Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 21 2016

Earnings vs. Estimates